MannKind Corporation

NASDAQ:MNKD

Biotechnology

Healthcare
$4.07 -0.51%

-$0.02 today

Market cap
$1.31B
Beta
1.11
P/E (TTM)
-50.3
EPS (TTM)
-$0.08
52W Low $2.23High $6.51

Volume 2.12M

Average 5.73M

MNKD EBITDA Margin

EBITDA as a percentage of revenue.

MannKind CorporationNASDAQ: MNKD

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to 2.7%

EBITDA Margin was 2.7% in Q1 FY2026, down 31.6 pp from a year earlier. On a trailing-twelve-month basis it was 7.6%, down 20.1 pp year over year. Over 3 fiscal years it widened by 64.3 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -3.2% for the fiscal year ending Dec 2026, down from 7.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
2.7%+5.0 pp QoQ
Last fiscal yearDec 2025
7.9%-19.2 pp YoY
LTMMar 2026
7.6%-20.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-31.6 pp+2.4 pp+34.0 pp
1 year-19.2 pp-11.1 pp+8.2 pp
3 years+64.3 pp+12.3 pp-52.1 pp
5 years+24.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
7.9%
Year-over-year change
-19.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How MNKD compares with its peers on the latest reported figures

  • MNKD's LTM Mar 2026 EBITDA Margin of 7.6% is the 4th highest of the 6 companies compared; the peer median is 14.7%.
  • Its year-over-year change of -20.1 pp is the 3rd highest of 4, against a peer median of +16.6 pp.
  • Over three fiscal years its change of +64.3 pp compares with a peer median of +1344.2 pp.
MNKD Competitors Peer median
EBITDA Margin for MNKD and competitors
Company Period LTM level YoY 3-year change
ORMPOramed Pharmaceuticals Inc.FY20253772.2% —+5140.2 pp
TBPHTheravance Biopharma, Inc.LTM Mar 2026129.8% +193.9 pp+275.9 pp
XERSXeris Biopharma Holdings, Inc.LTM Mar 202614.7% +16.6 pp+67.2 pp
MNKDMannKind CorporationLTM Mar 20267.6% -20.1 pp+64.3 pp
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026-194.1% -178.7 pp+2412.5 pp
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-1017.5% ——
AVLNAvalyn Pharma Inc. Common Stock—— ——
Peer median (excluding MNKD) 14.7%+16.6 pp+1344.2 pp

Competitors are the stored peer set for MNKD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.44M99.77M198.96M285.5M348.97M
Cost of Revenue38.86M57.5M62.77M76.6M61.16M
Gross Profit36.59M42.27M136.19M208.9M287.81M
Gross Margin48.5%42.4%68.5%73.2%82.5%
Research & Development12.31M19.72M31.28M45.89M66.35M
Selling, General & Admin77.42M91.47M94.31M94.33M144.14M
Operating Expenses83.61M106.38M127.51M136.32M249.01M
Depreciation & Amortization3.24M6.31M4.54M8.97M12.28M
EBITDA(61.11M)(56.32M)15.13M77.47M27.52M
EBITDA Margin-81.0%-56.4%7.6%27.1%7.9%
Operating Income(47.02M)(64.11M)8.68M72.59M38.8M
Operating Margin-62.3%-64.3%4.4%25.4%11.1%
Interest Income112K2.51M6.15M12.62M0
Interest Expense16.58M24.77M25.16M37.98M13.83M
Other Income / Expenses(33.9M)(23.29M)(19.06M)(42.07M)(37.39M)
Income Before Tax(80.93M)(87.4M)(10.38M)30.52M1.41M
Pre-Tax Margin-107.3%-87.6%-5.2%10.7%0.4%
Income Tax Expense001.56M2.93M(4.46M)
Net Income(80.93M)(87.4M)(11.94M)27.59M5.86M
Net Margin-107.3%-87.6%-6.0%9.7%1.7%
EPS (Basic)(0.37)(0.44)(0.04)0.100.02
EPS (Diluted)(0.37)(0.44)(0.04)0.100.02
Weighted Avg Shares249.24M257.09M267.01M274.42M305.64M
Weighted Avg Shares (Diluted)249.24M257.09M267.01M283.84M314.11M

MannKind Corporation

NASDAQ:MNKD

Intrinsic Alpha fair value

Locked

Current Price

$4.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.